Exactly. When insurance says they cover something, that should mean that it’s affordable to the patient. If they can’t afford it, then insurance wasn’t honest about covering it.

This is the right discussion for Congress to be having.

No Patient Left Behind I Am Biotech PhRMA The Economist

GPT-4 passed the mirror test in 3 interactions, during which its apparent self-recognition rapidly progressed.

In the first interaction, GPT-4 correctly supposes that the chatbot pictured is an AI “like” itself.

In the second interaction, it advances that understanding and…

At RA Capital, we all try to improve everything... board governance, IPO process, the IRA, insurance reform, healthcare economics literacy, and this one attempt at upgrading sour patch kids (can't be done, unlike everything else on this list).

What you may not know is that our…

Excellent piece. 'Price controls on novel medicine are innovation kryptonite'. Biosecure won't secure us if we don't support innovation and cap out of pocket costs for patients.

Interesting study- cell.com/cell-metabolis…

Fudge!!?!

PBMs replacing big pharma as the punching bag on #drugpricing . Good for patients and good for biotech endpts.com/ftcs-lina-khan… ht Matthew Herper $XBI

Honored to serve our community and neighbors alongside Life Science Cares Boston team and board!!

Professional, caring, and classy. Synlogic has pioneered so far. Sad day for patients and innovation.

Phenomenal accomplishment for cancer research! Stunning what teamwork can achieve.

We hit the $1 million goal for Damon Runyon Cancer Research Foundation. Thanks to all the hikers, sponsors, and individual donors. Celebration time! youtube.com/watch?v=UOAN0i…

Such a small tweak to IRA will make a big difference for future medicines. That you to these policymakers from both sides of aisle for doing the right thing.

And thank you to everyone who helped make the case for this 9-13 fix (technically 7-11 cause process starts 2y earlier).

Meanwhile, $RHHBY highlights two NMEs in oncology as having moved into phase 1:

RG6468 (new code for RO7566802), unknown mechanism

At height of opioid crisis during my tenure as ⁦I Am Biotech⁩ Chair, we developed industry principles to address crisis.

#1 was to rally industry innovation for non-addictive new Rx.

Today, we are one step closer to bringing this change for society! businesswire.com/news/home/2024…

I don’t watch a lot of live “television” but I’m pretty confident that advertisers promise of “AI” far outstrips any current capabilities of AI. People are getting setup for a bubble burst Marc Andreessen 🇺🇸

Signed ✅

Great week with the best team in biotech ⁦Nimbus Therapeutics⁩ #jpm2024

At JPM, you’ve seen me w my Life Science Cares pin on. LSC is an industry-wide effort to fight poverty & inequity. Join me supporting LSC's impact in our communities. Support LSC at #JPM2024 your gift will be matched by Gilead Sciences lnkd.in/eUcSMM3d

Great to be back in Union Square for #JPM2024 . Met several colleagues I haven’t seen in years while trying to take this selfie (all of whom appropriately poked fun at my pose). Interactions are a vital source of innovation in our industry and it’s great to get that energy back.

Honored to kickoff the Private Track at #jpm2024 (7:30am Monday!!) with new programs in immunology and data updates on other programs in the ⁦Nimbus Therapeutics⁩ pipeline. More details on LinkedIn and here:

businesswire.com/news/home/2024… linkedin.com/posts/jebkeipe…